A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.

A fusion protein including granzyme B, a cell penetrating peptide, a cleavage site, and a targeting moiety, a composition for cell membrane penetration comprising the fusion protein, and an anticancer composition comprising the fusion protein.

In one embodiment, the present invention provides a composition comprising a plurality of microcapsules, each comprising a shell and a core carrying an active agent selected from the group consisting of: (a) a non-hydrophilic active agent and (b) a hydrophilic active agent dissolved or suspended in an oil; wherein the shell comprises a polymeric coating, and wherein at least a portion of the microcapsules in a sample of the composition are spherical when the sample of the microcapsules is viewed in a scanning electron microscope with a magnification in the range of between ×2000 and ×50000.

In one embodiment, the present invention provides a composition comprising a plurality of microcapsules, each comprising a shell and a core carrying an active agent selected from the group consisting of: (a) a non-hydrophilic active agent and (b) a hydrophilic active agent dissolved or suspended in an oil; wherein the shell comprises a polymeric coating, and wherein at least a portion of the microcapsules in a sample of the composition are spherical when the sample of the microcapsules is viewed in a scanning electron microscope with a magnification in the range of between ×2000 and ×50000.

The present invention relates to the use of compounds that block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the α9α10 subtype of the nAChR.

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without inducing excessive hypotension. This document also provides methods and materials for inducing natriuretic activities within a mammal.

Novel peptidomimetic compounds are disclosed, compounds that inhibit protein-protein interactions (PPI) of epidermal growth factor receptors (EGFR), also called human epidermal growth factor receptors (HERs), and that block signaling for cell growth in HER2-overexpressed cancers. The novel peptidomimetics specifically bind the HER2 protein, and thereby inhibit dimerization. The peptidomimetics disrupt both HER2-HER3 and EGFR-HER2 heterodimer formation. The peptidomimetics can be used in the treatment of various types of HER2-overexpressed cancers, including lung, breast, and ovarian cancers.

A tumor-targeting peptide is disclosed. This tumor-targeting peptide comprises a typical motif with the general formula of: XX(Y/F) (D/E) (D/E) XX. The motif is selectively connected with 1-3 amino acids at the C-terminal and/or N-erminal. X represents any one of the twenty natural amino acids or the D type amino acids. The present invention also discloses that the peptide can not only target tumor vessels and tumor cells but also penetrate them and thus can be applied in tumor diagnosis and therapy.

The disclosure relates to a method for determining the risk that a human subject will develop a cancer, the method comprising quantifying the HLA triplets (HEAT) of the subject that are capable of binding to T cell epitopes in the amino acid sequence of tumor associated antigens. The disclosure also relates to methods of treating subjects who are determined to have an elevated risk of developing cancer.

Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin.